Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.7× sales vs its 0.7× historical median P/S.
Fair value ≈ $5.62 · price $5.54 today
Fair value · 1% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$MBIO $CPHI $GNPX $ALIM
CPHI: China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025.
In China, the incidence of dry eye disease is about 21%-30%, second only to myopia. According to the National Bureau of Statistics of China, the total population of the country by the end of 2023 is about 1.4 billion, and the number of dry eye disease patients in China has approached 400 million.
https://www.intratio.com/stock-forecast/ALIM ALIMERA SCIENCES INC Our algorithm deduces that this equity s value will decrease quickly and is not likely to present a long-term opportunity $ALIM
$ALIM ALIMERA SCIENCES INC The AI estimates that this stock s price action will lose ground in the coming days and is not likely to present a long-term opportunity
$ANIP $ALIM ANI Pharmaceuticals completes acquisition of Alimera Sciences
ANI Pharmaceuticals (ANIP) announced the completion of its previously announced acquisition of Alimera Sciences (ALIM). ANI continues to expect high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS with substantial accretion thereafter. The transaction is anticipated to deliver an additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology. ANI is maintaining its 2024 guidance for the standalone Company based on continued momentum across Cortrophin Gel and Generics and plans to provide 2024 guidance for the combined Company by no later than the Company's third quarter earnings call.
Under the terms of the merger agreement, ANI acquired all of the outstanding shares of Alimera for $5.50 per share. The Company also repaid $72.5 million of Alimera debt. Alimera investors received one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANI recently completed an offering of $316.25 million aggregate principal amount of 2.25% convertible senior notes due September 1, 2029. The Company utilized a majority of the net proceeds as well as cash from its balance sheet to repay in full its existing senior secured term loan facility.
The initial conversion price of the convertible notes is $74.11 per share. Concurrent with the convertible offering, the Company used $40.6 million of the net proceeds to enter into capped call transactions. The cap price of the capped call transactions is initially $114.02 per share, which represents a premium of 100% over the last reported sale price of the Company's common stock on August 7, 2024. The capped call transactions are expected generally to reduce the potential dilution to ANI's common stock upon any conversion of the notes up to the cap price of $114.02.
To fund the acquisition of Alimera, ANI entered into a new senior secured credit agreement consisting of a $325 million delayed draw term loan facility and $75 million revolving credit facility. On September 16, 2024 the Company drew the full $325 million term loan; the $75 million revolving credit facility remains un-drawn. The Company expects these capital structure changes to reduce interest expense by approximately $39 million on an annualized basis as compared to estimated interest expense that would have been incurred if the new principal amount of debt was subject to rates that would have applied under the previous debt capital structure.
$ALIM https://www.intratio.com/stock-forecast/ALIM The model lets us believe that this stock s value will decrease in the near future and has a neutral long-term outlook
$ANIP $ALIM ANI Pharmaceuticals, Alimera Sciences merger to close on September 16
ANI Pharmaceuticals (ANIP) and Alimera Sciences (ALIM) jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16.
$ALIM News Article ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
https://marketwirenews.com/news-releases/ani-pharmaceuticals-and-alimera-sciences-announce-cl-8438462376108955.html
$ALIM
https://www.intratio.com/stock-forecast/ALIM ALIMERA SCIENCES INC The predictive model assessed that this company s value is not likely to rise soon and has no clear long-term directional perspective $ALIM
